Biotechnology
Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma")announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfullycompleted patient ...
2026-10-31 13:00
4768
Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"
BOSTON, Oct. 30, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. J...
2026-10-31 00:00
3703
aphranel® Hosts European Physicians in China for Clinical Exchange
Week-Long Programme Under The Norns' Weave Examines Chinese Clinical Practice and Its Potential Applications in Europe SHANGHAI, Oct. 30, 2026 /PRNewswire/ -- aphranel®, the regenerative aesthetics brand of MOYOM Biotech, has launched a clinical exchange programme bringing European physicians to...
2026-10-30 17:00
2650
Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation
Preliminary responses observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumab Early antitumor activity also observed in squamous NSCLC, SCLC and prostate cancer SHANGHAI and HANGZHOU, China, Oct. 29, 2026 ...
2026-10-30 09:00
3648
Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or "Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting precisionbispecific antibodies for immunology and inflammation, today announced the pricing of ...
2026-10-30 08:15
4037
Yuyu Pharma Explores Animal Health as a New Pathway for Human Drug Innovation
SEOUL, South Korea, Oct. 29, 2026 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) CEO Robert Wonsang Yu shared the company's vision for connecting human and animal health at BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), highlighting how pharmaceutical research and development can create new opportunities ac...
2026-10-29 21:00
2893
United Imaging Healthcare Reports 19.43% Revenue Growth in First Nine Months of 2026, with Cumulative R&D Investment Exceeding RMB 10 Billion Since 2022
SHANGHAI, Oct. 29, 2026 /PRNewswire/ -- United Imaging Healthcare (688271.SH), a global innovator in advanced medical imaging technologies and intelligent healthcare solutions, reported revenue of RMB 10.58 billion for the first nine months of 2026, up 19.43% year-on-year. Sustained investment in...
2026-10-29 15:32
3653
From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment
Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International Reach MADRID and SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 recently concluded in Madrid. As a leading innovator in China's pharmaceuti...
2026-10-28 11:32
3629
Natural Field to Showcase Liposomal Delivery and Formulation Solutions at SupplySide Global 2026
LAS VEGAS, Oct. 27, 2026 /PRNewswire/ -- As nutrition brands explore increasingly complex product formulations, the relationship between functional ingredients, delivery technologies, and application-specific formulation design is becoming an important consideration in product development. Natura...
2026-10-27 23:09
2444
Registrational Phase III CLARIFY trial: Target number of participants achieved
SYDNEY, Oct. 27, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the registration...
2026-10-27 21:02
2836
New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA
* This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen of sac-TMT plus pembrolizumab accepted for review. * The Phase III OptiTROP-Lung06 study supporting this application showed that sac-TMT plus p...
2026-10-27 19:10
3625
Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026
SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. During this period, Hengrui reported revenue of RMB24.41 billion, representing a year-over-year increase of 5.26%. Product sales revenue was...
2026-10-27 18:04
3399
MEPSGEN Launches NanoCalibur® Mini for Small-Volume Nanoparticle Formulation
* Automated system enables rapid, reproducible formulation screening with minimal sample consumption * Completes the NanoCalibur® Series (Mini, Lab, Pro, GMP), supporting a seamless scale-up path from early research to GMP manufacturing BOSTON, Oct. 26, 2026 /PRNewswire/ -- MEPSGEN US, Inc., ...
2026-10-26 22:00
2423
Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
CAMBRIDGE, Mass., Oct. 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 gener...
2026-10-26 21:00
4448
TJ Biopharma Doses First Patient in Phase 1 Trial of TJ-C64B, a CLDN6x4-1BB Bispecific Antibody for CLDN6-Positive Solid Tumors
- TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading programs in this class globally - First patient dosing marks a key milestone for TJ Biopharma's next-generation innovation pipeline HANGZHOU, China, Oct....
2026-10-26 20:00
3221
WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model
SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- WuXi AppTec (Stock Codes: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first three quarters ending September 30, 2026 ("Reporting Peri...
2026-10-26 17:25
5174
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2026-10-26 17:18
2494
ESMO 2026 | Professors Jie Wang, Zhijie Wang and Jianchun Duan's Team Reports 95.2% Disease Control With LK101 Combination Maintenance Therapy in Advanced NSCLC
BEIJING, Oct. 25, 2026 /PRNewswire/ -- On October 24, 2026, in Madrid, Spain, the team of Professors Jie Wang, Zhijie Wang and Jianchun Duan at the Cancer Hospital, Chinese Academy of Medical Sciences, presented Phase 1b/2a results in a Rapid Oral session at ESMO Congress 2026. The study evaluate...
2026-10-26 11:27
3325
Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026
SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the preliminary positive research results of the investigator-initiated trial (CT041-CG4010, NCT06857786) in China o...
2026-10-26 08:30
5792
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
* The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value across treatment settings. SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PR...
2026-10-26 08:00
3863
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
46024
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
21435
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
18820
